Latest News - Movement Disorders

Friday, January 18, 2019

Valbenazine Reduces Involuntary Movements in Patients with Mood Disorders

A post-hoc analysis of data from a clinical trial of valbenazine (Ingrezza; Neurocrine Biosciences, Inc., San Diego, CA) has been published in the Journal of Affective Disorders. This analysis sh…

Read the full story

Thursday, January 17, 2019

First Patients Enrolled in Trial of Wearable Neurostimulation Device for Treating Essential Tremor

The Pacific Movement Disorders Center at Pacific Neuroscience Institute announced that the first patients have been enrolled into a trial of a wearable, external, and wireless neuromodulation device (…

Read the full story

Wednesday, January 09, 2019

Breakthrough Device Designation Granted to Brain-Monitoring Technology

The Food and Drug Administration has granted breakthrough device designation to a brain health monitoring technology (Neurametrix; San Francisco, CA). The approved use is monitoring Parkinson’s …

Read the full story

Thursday, January 03, 2019

American Academy of Neurology Call for Uniformity in Brain Death Standards

Noting that only 1 state, Nevada, has adopted legislation requiring use of medically accepted guidelines for determining brain death, the American Academy of Neurology (AAN) is calling for action on t…

Read the full story

Wednesday, January 02, 2019

The Cost of Caring: Those Who Care for Loved Ones with Parkinson’s Lose Income Too

In a study published in the journal Movement Disorders, researchers studied the economic impact of caring for someone with Parkinson’s disease (PD) in the first 5 years of diagnosis. Previo…

Read the full story

Wednesday, December 26, 2018

Levodopa Inhalation Powder for Treatment of OFF Periods of Parkinson’s Approved

The Food and Drug Administration (FDA) has approved levodopa inhalation powder (Inbrija; Acorda Therapeutics, Ardsley, NY) for the intermittent treatment of OFF episodes in patients with Parkinson&rsq…

Read the full story

Wednesday, December 26, 2018

Study Defines Risk Factors for REM Sleep Behavior Disorder

A study published in Neurology online found that taking antidepressants for depression or having anxiety or post-traumatic stress disorder (PTSD) are correlated with the disruptive and somet…

Read the full story

Friday, November 30, 2018

Emerging Gene Therapy for Parkinson’s Disease Creates New Brain Circuits

A recent study found that gene therapy in development for treatment of patients with Parkinson's disease creates new circuits in the brain associated with improved movement.  In the study …

Read the full story

Wednesday, November 28, 2018

Biases in Dementia Screening Tools

Brief cognitive tests are useful screening tools for dementia in the primary care setting; however, a study published in the journal Neurology Clinical Practice shows that 3 of the most comm…

Read the full story

Friday, November 16, 2018

Digital Health Coach Assists Patients with Parkinson’s Disease

Patients suffering from Parkinson’s disease (PD), as well as their caregivers and families, can utilize a new app called a “digital health coach” for continuous support as they face …

Read the full story

Wednesday, November 14, 2018

Study Confirms Benefits of Laser Interstitial Thermal Therapy

A prospective, multi-center clinical study of 42 patients with brain lesions that recurred after stereotactic radiosurgery (SRS) for metastatic brain tumors showed positive outcomes for lase…

Read the full story

Friday, November 02, 2018

Effect of Pimavanserin for Parkinson’s Disease Psychosis Found Larger in Patients with Impaired Cognition

A post hoc analysis of data from the 6‐week phase 3 trial (NCT01174004) of pimavanserin (Nuplazid; Acadia Pharmaceuticals, San Diego, CA) in patients with Parkinson’s disease psychosis (PDP) h…

Read the full story

Tuesday, October 30, 2018

Positive Top-Line Results Announced from Phase 2 Study of Pimavanserin for Adjunctive Treatment of Major Depressive Disorder

Pimavanserin (Nuplazid; Acadia Pharmaceuticals, San Diego, CA), already approved for treatment of patients with Parkinson’s disease (PD) psychosis is also being studied as a potential adjunctive…

Read the full story

Tuesday, October 09, 2018

Positive Two-Year Outcomes for Treatment of Essential Tremor With Focused Ultrasound

Patients with medically refractory essential tremor treated with magnetic resonance-guided focused ultrasound (MRgFUS) thalamotomy had a mean 43.4% reduction in their scores on the Clinical Rating Sca…

Read the full story

Thursday, October 04, 2018

Shortage of Sinemet Attribute to Manufacturing and Forecasting Issues

The carbidopa-levodopa distributed under the brand names Sinemet and Sinemet Plus by Merck &Co. (Kenilworth, NJ) is out of stock and expected to be on back order through the first quarter of 2019.…

Read the full story
Load More